These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24212387)

  • 21. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.
    Okonkwo OC; Alosco ML; Griffith HR; Mielke MM; Shaw LM; Trojanowski JQ; Tremont G;
    Arch Neurol; 2010 Jun; 67(6):688-96. PubMed ID: 20558388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.
    Desikan RS; McEvoy LK; Thompson WK; Holland D; Brewer JB; Aisen PS; Sperling RA; Dale AM;
    Arch Neurol; 2012 Jun; 69(6):709-13. PubMed ID: 22529247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.
    Llibre-Guerra JJ; Li Y; Schindler SE; Gordon BA; Fagan AM; Morris JC; Benzinger TLS; Hassenstab J; Wang G; Allegri R; Berman SB; Chhatwal J; Farlow MR; Holtzman DM; Jucker M; Levin J; Noble JM; Salloway S; Schofield P; Karch C; Fox NC; Xiong C; Bateman RJ; McDade E
    JAMA Netw Open; 2019 Dec; 2(12):e1917126. PubMed ID: 31825500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
    Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
    JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults.
    Nation DA; Edland SD; Bondi MW; Salmon DP; Delano-Wood L; Peskind ER; Quinn JF; Galasko DR
    Neurology; 2013 Dec; 81(23):2024-7. PubMed ID: 24225352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
    Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.
    Roe CM; Fagan AM; Grant EA; Marcus DS; Benzinger TL; Mintun MA; Holtzman DM; Morris JC
    Arch Neurol; 2011 Sep; 68(9):1145-51. PubMed ID: 21911695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Irwin DJ; Fedler J; Coffey CS; Caspell-Garcia C; Kang JH; Simuni T; Foroud T; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Weintraub D; Mollenhauer B; Galasko DR; Siderowf A; Marek K; Trojanowski JQ; Shaw LM;
    Ann Neurol; 2020 Sep; 88(3):574-587. PubMed ID: 32542885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
    Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
    Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
    J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.
    Xiong C; Jasielec MS; Weng H; Fagan AM; Benzinger TL; Head D; Hassenstab J; Grant E; Sutphen CL; Buckles V; Moulder KL; Morris JC
    Neurology; 2016 Apr; 86(16):1499-506. PubMed ID: 27009258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.